Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Acitretin
Drug ID BADD_D00036
Description An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Indications and Usage For the treatment of severe psoriasis in adults.
Marketing Status approved
ATC Code D05BB02
DrugBank ID DB00459
KEGG ID D02754
MeSH ID D017255
PubChem ID 5284513
TTD Drug ID D05QDC
NDC Product Code 17337-0003; 59981-011; 0093-1136; 0115-1752; 42291-087; 62147-0145; 0115-1751; 42794-081; 0378-7020; 71214-0698; 42291-088; 58159-058; 71052-692; 0115-1753; 17337-0004; 71214-0667; 0115-1750; 71214-0668; 71214-0669; 42291-086; 42794-080; 0093-1135; 0093-1138; 62147-0146; 76055-0001; 42794-083; 0378-7023
UNII LCH760E9T7
Synonyms Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652
Chemical Information
Molecular Formula C21H26O3
CAS Registry Number 55079-83-9
SMILES CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haptoglobin decreased13.02.03.001--
Haptoglobin increased13.02.03.002--Not Available
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.004--Not Available
Hepatitis F11.05.28.005; 09.01.09.010--Not Available
Herpes simplex23.11.05.004; 11.05.02.001--Not Available
High density lipoprotein decreased13.12.01.003--Not Available
Hordeolum11.01.06.002; 06.04.04.006--Not Available
Hyperaesthesia23.03.03.080; 17.02.06.004--Not Available
Hypercholesterolaemia14.08.01.0010.001875%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkeratosis23.01.01.001--
Hypersensitivity10.01.03.003--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypertrichosis23.02.04.002--
Hypertriglyceridaemia14.08.02.001--
Hypervitaminosis A14.12.04.002--Not Available
Hypoaesthesia17.02.06.023; 23.03.03.081--Not Available
Hypotension24.06.03.0020.001250%
Immune system disorder10.02.01.001--Not Available
Impaired healing08.03.02.0010.001250%Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.010--
Insomnia19.02.01.002; 17.15.03.002--
Intentional self-injury19.12.01.002; 12.01.08.036--Not Available
Intermittent claudication24.04.03.001--Not Available
Intracranial pressure increased17.07.02.002--Not Available
Iritis10.02.01.022; 06.04.03.002--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene